The bill will also:
- increase the range of professions able to prescribe medicines in low-risk circumstances, reducing unnecessary GP appointments
- introduce new regulations on medical devices, such as pacemakers, breast implants and ultrasound imagers, to ensure patient safety
The new bill means hospitals can use patient tissue and DNA samples to tailor treatments to individual patients when other medicines have failed, or to develop drugs that have a shelf-life of minutes and would otherwise be unavailable to them. This has the potential to streamline access to treatments for patients with rare cancers and brain tumours.
The bill also allows the sector to increase the range of professions able to prescribe medicines in low-risk circumstances, as midwives and paramedics do now with pain relief and physiotherapists with anti-inflammatories. This means the NHS can make the best use of its highly skilled workforce, saving patients’ time and reducing unnecessary GP appointments.
There will be safeguards and limits on what medications are eligible. The government will work with the NHS and stakeholders to determine what medicines could be eligible and in what circumstances.
The bill will also allow the government to ensure medical devices are subject to the highest standards of regulation, further boosting patient safety and ensuring the UK leads the way in developing pioneering health technology. With a faster, more flexible system in place, regulators will be able to respond to changes in technology or patient safety concerns as soon as possible.
Companies will need to register medical devices with the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring suppliers follow strict safety checks and enabling tough enforcement action if something goes wrong.
The Health and Social Care Secretary will be given the power to disclose specific information about devices to members of the public and the healthcare system, subject to appropriate safeguards, when there are serious patient safety concerns.
The bill is scheduled for its second reading on 2 March 2020. BIVDA will be following its progress closely and engaging with the government to ensure that IVDs are supported and recognised where appropriate in the legislation.